Back to Search
Start Over
Supplementary Table 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Supplementary Table 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Table 3. ROC curves correlating BCR-ABL/ABL levels at diagnosis with 8-year estimates of OS, TFS, FFS, EFS and Optimal Response
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....d7b2ae601363caf39ea8351ceb833045
- Full Text :
- https://doi.org/10.1158/1078-0432.22466627.v1